80 related articles for article (PubMed ID: 12860346)
1. Cervical response to vaccination against HPV16 E7 in case of severe dysplasia.
Simon P; Buxant F; Hallez S; Burny A; Fayt I; Anaf V; Noël JC
Eur J Obstet Gynecol Reprod Biol; 2003 Aug; 109(2):219-23. PubMed ID: 12860346
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
3. Prospects for therapeutic HPV vaccines.
Trimble CL
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S249-50. PubMed ID: 16419216
[No Abstract] [Full Text] [Related]
4. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
de Vos van Steenwijk PJ; Ramwadhdoebe TH; Löwik MJ; van der Minne CE; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Hellebrekers BW; Welters MJ; van Poelgeest MI; Melief CJ; Kenter GG; van der Burg SH
Cancer Immunol Immunother; 2012 Sep; 61(9):1485-92. PubMed ID: 22684521
[TBL] [Abstract][Full Text] [Related]
5. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients.
Kawana K; Adachi K; Kojima S; Taguchi A; Tomio K; Yamashita A; Nishida H; Nagasaka K; Arimoto T; Yokoyama T; Wada-Hiraike O; Oda K; Sewaki T; Osuga Y; Fujii T
Vaccine; 2014 Oct; 32(47):6233-9. PubMed ID: 25258102
[TBL] [Abstract][Full Text] [Related]
6. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals.
Luxton JC; Rowe AJ; Cridland JC; Coletart T; Wilson P; Shepherd PS
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1585-93. PubMed ID: 8758003
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.
Maldonado L; Teague JE; Morrow MP; Jotova I; Wu TC; Wang C; Desmarais C; Boyer JD; Tycko B; Robins HS; Clark RA; Trimble CL
Sci Transl Med; 2014 Jan; 6(221):221ra13. PubMed ID: 24477000
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia.
Frazer IH; Quinn M; Nicklin JL; Tan J; Perrin LC; Ng P; O'Connor VM; White O; Wendt N; Martin J; Crowley JM; Edwards SJ; McKenzie AW; Mitchell SV; Maher DW; Pearse MJ; Basser RL
Vaccine; 2004 Nov; 23(2):172-81. PubMed ID: 15531034
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.
Daniel D; Chiu C; Giraudo E; Inoue M; Mizzen LA; Chu NR; Hanahan D
Cancer Res; 2005 Mar; 65(5):2018-25. PubMed ID: 15753402
[TBL] [Abstract][Full Text] [Related]
10. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18.
Smith KL; Tristram A; Gallagher KM; Fiander AN; Man S
Int Immunol; 2005 Feb; 17(2):167-76. PubMed ID: 15623547
[TBL] [Abstract][Full Text] [Related]
11. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
13. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.
Roman LD; Wilczynski S; Muderspach LI; Burnett AF; O'Meara A; Brinkman JA; Kast WM; Facio G; Felix JC; Aldana M; Weber JS
Gynecol Oncol; 2007 Sep; 106(3):558-66. PubMed ID: 17631950
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix.
Monnier-Benoit S; Mauny F; Riethmuller D; Guerrini JS; Căpîlna M; Félix S; Seillès E; Mougin C; Prétet JL
Gynecol Oncol; 2006 Jul; 102(1):22-31. PubMed ID: 16427684
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
[TBL] [Abstract][Full Text] [Related]
17. Single-cell cytokine analysis allows detection of cervical T-cell responses against human papillomavirus type 16 L1 in women infected with genital HPV.
Passmore JA; Burch VC; Shephard EG; Marais DJ; Allan B; Kay P; Rose RC; Williamson AL
J Med Virol; 2002 Jun; 67(2):234-40. PubMed ID: 11992584
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
Alvarez RD; Huh WK; Bae S; Lamb LS; Conner MG; Boyer J; Wang C; Hung CF; Sauter E; Paradis M; Adams EA; Hester S; Jackson BE; Wu TC; Trimble CL
Gynecol Oncol; 2016 Feb; 140(2):245-52. PubMed ID: 26616223
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7.
Höpfl R; Heim K; Christensen N; Zumbach K; Wieland U; Volgger B; Widschwendter A; Haimbuchner S; Müller-Holzner E; Pawlita M; Pfister H; Fritsch P
Lancet; 2000 Dec; 356(9246):1985-6. PubMed ID: 11130532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
